- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.07. | Neumora reports favorable toxicology results for obesity drug | 11 | Investing.com | ||
| NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.07. | Neumora meldet positive Toxikologie-Daten für Adipositas-Wirkstoff | 2 | Investing.com Deutsch | ||
| 27.07. | Neumora Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.07. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 | 233 | GlobeNewswire (Europe) | WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target... ► Artikel lesen | |
| 22.06. | Neumora stock price target lowered to $4 by Mizuho on trial failure | 8 | Investing.com | ||
| 17.06. | Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant's Upcoming Depression Data | 12 | Insider Monkey | ||
| 16.06. | Neumora depression drug fails; EnGene to cut 50% of staff | 4 | BioPharma Dive | ||
| 16.06. | Needham cuts Neumora stock price target on navacaprant discontinuation | 10 | Investing.com | ||
| 16.06. | Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy | 10 | Investing.com | ||
| 15.06. | Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail | 3 | Benzinga.com | ||
| 15.06. | Neumora plummets as phase 3 navacaprant data misses key goal | 3 | Seeking Alpha | ||
| 15.06. | Neumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies | 5 | FierceBiotech | ||
| 15.06. | Neumora stoppt Depressionsmedikament nach Studienfehlschlag und kündigt Stellenabbau an | 6 | Investing.com Deutsch | ||
| 15.06. | Neumora Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update | 285 | GlobeNewswire (Europe) | Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer's disease... ► Artikel lesen | |
| 29.05. | Neumora Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 07.05. | Neumora Therapeutics, Inc. - 8-K, Current Report | 25 | SEC Filings | ||
| 30.03. | Guggenheim reiterates Neumora stock rating on pipeline progress | 24 | Investing.com | ||
| 30.03. | Stifel reiterates Neumora Therapeutics stock Hold rating at $3 | 3 | Investing.com | ||
| 30.03. | Stifel bestätigt 'Hold'-Rating für Neumora Therapeutics mit Kursziel von 3 US-Dollar | 4 | Investing.com Deutsch |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,70 | +3,33 % | BioNTech SE und Emyria Limited: Wenn schlafende Biotech-Riesen erwachen und datenstarke Plattformen den Markt erobern | ||
| MODERNA | 51,36 | +0,37 % | Moderna startet Phase-1-Studie mit Ebola-Impfstoffkandidat | Moderna hat eine Phase-1-Studie mit seinem Impfstoffkandidaten mRNA-1469 gegen das Bundibugyo-Ebolavirus (BDBV) begonnen. Nach der Genehmigung durch die kanadische Gesundheitsbehörde wurden in Kanada... ► Artikel lesen | |
| AMGEN | 355,85 | +0,13 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,40 | -0,82 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| ILLUMINA | 162,12 | -0,31 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,250 | -1,35 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 45,180 | +0,30 % | BTIG cuts Tempus AI stock price target to $70 on model update | ||
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 55,16 | +6,90 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht |
Das Unternehmen NEUMORA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-0,31 %) liegt der Kurs bei 1,625 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.